BioNTech ends vaccine production, cutting up to 1,860 jobs

BioNTech is ending Covid vaccine production in Germany and cutting up to 1,860 jobs (around 22 percent). Those affected include Marburg (around 540), Idar-Oberstein (around 440) and around 820 jobs at the acquired company CureVac; expected savings of up to €500 mn per year from 2029. Update (28.09.2026): BioNTech found no buyers for its three German plants; they will close in stages – Tübingen at the end of 2027, Marburg in early 2028, Idar-Oberstein at the end of 2028 – affecting about 1,800 employees according to the company (ZDFheute, 28.09.2026).